7773 Stock Overview
Engages in the research and development of immune system-related services. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
FullHope Biomedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$37.40 |
| 52 Week High | NT$70.30 |
| 52 Week Low | NT$37.65 |
| Beta | 0 |
| 1 Month Change | -8.89% |
| 3 Month Change | -45.95% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.88% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 7773 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -3.4% | 1.7% | 0.3% |
| 1Y | n/a | 2.1% | 27.4% |
Return vs Industry: Insufficient data to determine how 7773 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 7773 performed against the TW Market.
Price Volatility
| 7773 volatility | |
|---|---|
| 7773 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 7773's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 7773's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | n/a | www.fhb.com.tw |
FullHope Biomedical Co.,Ltd. engages in the research and development of immune system-related services. It develops FHCT001 and FHCT003, an immune cell therapies for cancer; and FHCT002, an auto-immune cell therapy, as well as diagnostic tools.
FullHope Biomedical Co.,Ltd. Fundamentals Summary
| 7773 fundamental statistics | |
|---|---|
| Market cap | NT$1.51b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7773 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7773 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7773 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:01 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
FullHope Biomedical Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|